Pseudoephedrine hydrochloride

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the temporary relief of nasal congestion associated with the common cold, hay fever, or other upper respiratory allergies. It effectively reduces swelling of the nasal passages and alleviates sinus pressure.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Adults and children aged 12 years and over are instructed to swallow one whole tablet with water once every 24 hours. It is imperative that the dosage does not exceed one tablet within a 24-hour period. The tablet must not be divided, crushed, chewed, or dissolved prior to ingestion. It is important to note that the tablet does not completely dissolve and may be observed in the stool, which is a normal occurrence.

This product is contraindicated for use in children under 12 years of age.

Contraindications

Use of this product is contraindicated in the following situations:

Patients should discontinue use and consult a healthcare professional if they experience nervousness, dizziness, or sleeplessness. Additionally, if symptoms do not improve within 7 days or are accompanied by a fever, medical advice should be sought. Persistent abdominal pain or vomiting also necessitates cessation of use and consultation with a healthcare provider. It is essential to adhere to the recommended dosage, as exceeding it may lead to adverse effects.

Warnings and Precautions

It is imperative that this product not be used concurrently with prescription monoamine oxidase inhibitors (MAOIs), which are medications prescribed for depression, psychiatric or emotional conditions, or Parkinson’s disease. Additionally, this product should not be taken for a minimum of two weeks following the discontinuation of an MAOI. Healthcare professionals should advise patients to consult with a doctor or pharmacist if there is uncertainty regarding the presence of an MAOI in their current prescription medications.

In the event of an overdose, immediate medical assistance is required. Patients should be instructed to contact a Poison Control Center or seek emergency medical help without delay. The national Poison Control Center can be reached at 1-800-222-1222.

Patients should discontinue use and consult a healthcare provider if they experience any of the following symptoms: nervousness, dizziness, or sleeplessness. Additionally, if symptoms do not improve within seven days or are accompanied by a fever, or if the patient experiences persistent abdominal pain or vomiting, it is crucial to seek medical advice promptly.

Side Effects

Patients should be aware of the potential adverse reactions associated with the use of this medication. Serious adverse reactions may occur, particularly in individuals who are currently taking or have recently discontinued a prescription monoamine oxidase inhibitor (MAOI). The use of this medication is contraindicated in such cases, as it may lead to significant health risks.

Common adverse reactions reported include nervousness, dizziness, and sleeplessness. Patients are advised to discontinue use if these symptoms occur. Additionally, if symptoms do not improve within 7 days, or if they are accompanied by a fever, patients should seek medical attention. Persistent abdominal pain or vomiting is also a reason to stop use and consult a healthcare provider.

Patients with pre-existing conditions should exercise caution and consult a doctor before using this medication. This includes individuals with heart disease, high blood pressure, thyroid disease, diabetes, or those experiencing trouble urinating due to an enlarged prostate gland. Furthermore, patients with a history of bowel obstruction or narrowing should be particularly vigilant, as the medication may rarely cause bowel obstruction, especially in those with severe narrowing of the bowel (esophagus, stomach, or intestine).

Monitoring for these adverse reactions is essential to ensure patient safety and effective management of any potential complications.

Drug Interactions

The use of pseudoephedrine is contraindicated in patients who are currently taking a prescription monoamine oxidase inhibitor (MAOI) or within two weeks of discontinuing an MAOI. Co-administration may result in serious interactions due to the pharmacodynamic effects of both drug classes. It is essential for healthcare providers to monitor patients closely and consider alternative therapies during this period to avoid potential adverse effects.

Packaging & NDC

Below are the non-prescription pack sizes of Pseudoephedrine Hydrochloride. Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 12 years of age should not use this product. For adolescents aged 12 years and older, the recommended dosage is one whole tablet swallowed with water every 24 hours, with a maximum of one tablet in a 24-hour period.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully considered in these populations to ensure the safety of both the mother and the fetus or infant.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data regarding the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment may not have specific dosage adjustments, special monitoring, or safety considerations outlined in the available data. Therefore, healthcare professionals should exercise caution when prescribing to this population, as the lack of information necessitates careful clinical judgment regarding the use of the medication in individuals with reduced kidney function. Regular monitoring of renal function is advisable to ensure patient safety and efficacy of treatment.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

There is currently no specific information available regarding overdosage for this medication. Healthcare professionals are advised to monitor patients closely for any signs of adverse effects or symptoms that may arise from excessive dosing.

In the event of suspected overdosage, it is recommended that healthcare providers initiate supportive care and symptomatic treatment as necessary. Patients should be evaluated for potential complications, and appropriate interventions should be implemented based on the clinical presentation.

For further guidance, healthcare professionals may refer to established protocols for managing drug overdosage or consult a poison control center.

Nonclinical Toxicology

If pregnant or breastfeeding, it is advised to consult a health professional prior to use. Rarely, the use of tablets of this kind may lead to bowel obstruction, particularly in individuals with significant narrowing of the bowel, which may involve the esophagus, stomach, or intestine.

No relevant information regarding nonclinical toxicology or animal pharmacology and toxicology has been provided in the insert.

Postmarketing Experience

Postmarketing experience has identified rare cases of bowel obstruction associated with the use of pseudoephedrine hydrochloride, particularly in individuals with severe narrowing of the bowel, including the esophagus, stomach, or intestine. These events were reported voluntarily or through surveillance programs.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center at 1-800-222-1222 in the event of an overdose. It is crucial for patients to understand the importance of prompt action in such situations to ensure their safety and well-being.

Storage and Handling

The product is supplied in individual blister units. Each blister unit must remain intact; do not use if the unit is open or torn.

For optimal storage conditions, the product should be maintained at a temperature range of 20° to 25°C (68° to 77°F). It is essential to ensure that the storage environment adheres to these temperature guidelines to preserve the integrity and efficacy of the product.

Additional Clinical Information

The medication is administered orally, with both adults and children instructed to swallow one whole tablet with water every 24 hours. For patients aged 12 years and older, it is important not to exceed one tablet within a 24-hour period, and the tablet should not be divided, crushed, chewed, or dissolved.

Clinicians should counsel patients to consult a health professional if they are pregnant or breastfeeding. Additionally, it is crucial to keep the medication out of reach of children. In the event of an overdose, patients should seek medical assistance or contact a Poison Control Center immediately at 1-800-222-1222.

Drug Information (PDF)

This file contains official product information for Pseudoephedrine Hydrochloride, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)